Literature DB >> 8474076

Patient preferences for nonsteroidal antiinflammatory drug related gastrointestinal complications and their prophylaxis.

S E Gabriel1, M E Campion, W M O'Fallon.   

Abstract

We conducted a pilot study examining the relative preferences for various nonsteroidal antiinflammatory drug associated adverse gastrointestinal events and misoprostol prophylaxis for these events. Thirty patients with rheumatoid arthritis volunteered to participate. A trained nurse interviewer administered the structured pretested interview. Respondents rated 18 hypothetical health states on a category rating scale with anchors at 0 (immediate death) and 100 (full health for life). Linear contrasts were created to test the null hypotheses of equal preferences, using t tests for correlated means. Our results suggest that respondents place a high value on the avoidance of (in order of decreasing importance) surgery, hospitalization, prophylaxis induced diarrhea and uncomplicated ulcer requiring outpatient treatment. The avoidance of ulcer symptoms (primarily dyspepsia) and the inconvenience of an additional medication taken 4 times daily (in the absence of diarrhea) appeared to be substantially less important from these patients' perspective. Further work is underway to confirm these preliminary findings.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8474076

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

Review 1.  Economic and quality-of-life impact of NSAIDs in rheumatoid arthritis: A conceptual framework and selected literature review.

Authors:  S E Gabriel; E L Matteson
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

2.  Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.

Authors:  Jeroen P Jansen; Sabine Gaugris; Ernest H Choy; Andrew Ostor; Julian T Nash; Wiro Stam
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.

Authors:  Andrew Moore; Ceri Phillips; Elke Hunsche; James Pellissier; Simone Crespi
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Aspirin for primary prevention of cardiovascular events.

Authors:  F A Augustovski; S B Cantor; C T Thach; S J Spann
Journal:  J Gen Intern Med       Date:  1998-12       Impact factor: 5.128

5.  Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway.

Authors:  Jeroen P Jansen; Stephanie D Taylor
Journal:  Int J Rheumatol       Date:  2011-06-24

6.  Factors Affecting Quality of Life and Satisfaction in Patients with Arthritis after Change to a Fixed-Dose Naproxen/Esomeprazole Combination Drug.

Authors:  Daehyun Park; Yonguk Kwon
Journal:  Clin Orthop Surg       Date:  2020-02-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.